Comparing Transcatheter Tricuspid Valve Repair to Medical Therapy

Although severe tricuspid regurgitation (TR) is associated with increased morbidity and mortality, randomized trials of transcatheter treatment have demonstrated improvements only in quality of life (QOL), with trends toward reductions in hospitalization for heart failure (HF) and mortality. In this randomized, partially manufacturer-funded German multicenter trial, patients with severe TR and at advanced risk for heart-failure events received medical therapy with or without tricuspid valve repair, primarily (98%) transcatheter edge-to-edge repair (T-TEER).